Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/18374| Title: | Chemoimmunotherapy May Not Be Dead Yet in Chronic Lymphocytic Leukemia, But Fludarabine Plus Cyclophosphamide Plus Rituximab Is Potentially Facing Life Support. | Austin Authors: | Opat, Stephen;Hawkes, Eliza A | Affiliation: | Austin Health, Heidelberg, Victoria, Australia Monash University, Melbourne, Australia Monash Health, Clayton, Australia Eastern Health, Box Hill, Australia |
Issue Date: | 20-Dec-2017 | Date: | 2017-11-03 | Publication information: | Journal of Clinical Oncology 2017; 35(36): 4093-4094 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/18374 | DOI: | 10.1200/JCO.2017.75.4721 | Journal: | Journal of Clinical Oncology | PubMed URL: | 29099632 | Type: | Journal Article |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.